Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107150 | 0.91 | KDM4E (0.69) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28891615 | 0.83 | MEN1 (0.54) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8807231 | 0.80 | CHRM3 (0.54) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19953554 | 0.79 | ALDH1A1 (0.84) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27075239 | 0.79 | MITF (0.51) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15858966 | 0.79 | KDM4E (0.55) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2712659 | 0.78 | MEN1 (0.62) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11407980 | 0.76 | MEN1 (0.65) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15858930 | 0.76 | MITF (0.45) | MITFALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8430674 | 0.76 | MITF (0.59) | MITFALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585241-A | AT2R antagonists and uses thereof | 伊莱利利公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-12122750-B2 | AT2R antagonists and uses thereof | ELI LILLY AND COMPANY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | MITF 1398/4885ALDH1A1 1261/4885SMN1; SMN2 3634/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | MITF 454/4885ALDH1A1 224/4885SMN1; SMN2 3450/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | MITF 1366/4885ALDH1A1 1253/4885SMN1; SMN2 3687/4885 |
| US-12122750-B2 | AT2R antagonists and uses thereof | AGTR2, AGTR1, AVPR2 | MITF 1398/4885ALDH1A1 1261/4885SMN1; SMN2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.